Zobrazeno 1 - 10
of 407
pro vyhledávání: '"Rodrigo E Mendes"'
Publikováno v:
Antibiotics, Vol 13, Iss 6, p 564 (2024)
We evaluated the activities of aztreonam/avibactam and recently approved β-lactamase inhibitor combinations (BLICs) to compare the antimicrobial susceptibility patterns of Enterobacterales and Pseudomonas aeruginosa isolated from intensive care unit
Externí odkaz:
https://doaj.org/article/08871ef02f3243d7b65bcb044824b4f6
Autor:
Mariana Castanheira, Timothy B. Doyle, Cory M. Hubler, Timothy D. Collingsworth, Sean DeVries, Rodrigo E. Mendes
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 31, Iss , Pp 72-79 (2022)
ABSTRACT: Objectives: Whole genome and transcriptome analysis of 213 Pseudomonas aeruginosa isolates resistant to antipseudomonal β-lactams collected in 30 countries was performed to evaluate resistance mechanisms against these agents. Methods: Isol
Externí odkaz:
https://doaj.org/article/63b262aa04404b89bb2fb27c4b4c745a
Autor:
Rodrigo E. Mendes, S. J. Ryan Arends, Jennifer M. Streit, Ian Critchley, Nicole Cotroneo, Mariana Castanheira
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 1 (2023)
ABSTRACT Tebipenem pivoxil is an oral broad-spectrum carbapenem. This study evaluated the activity of tebipenem and comparators against UTI Enterobacterales from US hospitals (2019–2020). 3,576 Enterobacterales causing UTI in 52 centers in 9 US Cen
Externí odkaz:
https://doaj.org/article/173addc9937b4bc3a445f4b1e613e521
Publikováno v:
International Journal of Infectious Diseases, Vol 116, Iss , Pp 306-312 (2022)
ABSTRACT: Background: High-dose cefepime-tazobactam (WCK 4282) is currently under clinical development at a dosage of 2 grams/2 grams every 8 hours with prolonged infusion (90 minutes). Objective: To evaluate the in vitro activity of high-dose cefepi
Externí odkaz:
https://doaj.org/article/5081ff46a758456c84fd75e8958c5a56
Publikováno v:
International Journal of Infectious Diseases, Vol 107, Iss , Pp 92-100 (2021)
Objectives: The antimicrobial activity of tedizolid and comparators was evaluated against a large worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae isolates recovered from patients with pneumonia. Methods: Clinical isolates w
Externí odkaz:
https://doaj.org/article/5767835ccdce4456a8c641299cbf2705
Publikováno v:
International Journal of Infectious Diseases, Vol 113, Iss , Pp 279-281 (2021)
Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI). Objectives: To evaluate the in vitro activity of ceftazidime
Externí odkaz:
https://doaj.org/article/bf9c27dc44894de6a4e64077bcd0288a
Autor:
Helio S. Sader, Cecilia G. Carvalhaes, Jennifer M. Streit, S.J. Ryan Arends, Rodrigo E. Mendes
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 24, Iss , Pp 48-52 (2021)
Objectives: To evaluate the in vitro activity of dalbavancin compared with vancomycin, daptomycin and other agents against a large collection of coagulase-negative staphylococci (CoNS) isolates. Methods: A total of 5088 CoNS causing clinically signif
Externí odkaz:
https://doaj.org/article/919522e538344c2587d60fde2191e6c7
Publikováno v:
International Journal of Infectious Diseases, Vol 102, Iss , Pp 524-528 (2021)
Objective: To evaluate the antimicrobial activity of ceftaroline against Staphylococcus aureus isolated from patients with infective endocarditis (IE). Methods: 23,833 S. aureus isolates were collected consecutively from patients with bloodstream inf
Externí odkaz:
https://doaj.org/article/97362aa537324e7c9b3a149bd9eeb41c
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 23, Iss , Pp 439-444 (2020)
Objectives: Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis are urinary tract infection (UTI) pathogens and extended spectrum β-lactamase (ESBL)-producing pathogens exhibit co-resistance to oral fluoroquinolones (FQ) and trimethoprim-s
Externí odkaz:
https://doaj.org/article/187899a9ca1b4f1a8ea375a1124cec41
Publikováno v:
International Journal of Infectious Diseases, Vol 107, Iss , Pp 69-71 (2021)
The activities of dalbavancin and comparator agents were evaluated against Staphylococcus aureus isolated from the lower respiratory tract of cystic fibrosis (CF) and non-CF patients with pneumonia. Bacterial isolates (n = 357) were collected from CF
Externí odkaz:
https://doaj.org/article/c76fc1d89024419c8cb4b0569ee2f118